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INTRO DUCTION
A single drug may cause various pharmacological effects which are gene- 
rated by means of a reaction of drug molecules with the same type of recep- 
tors but also as a result of interaction with different types o f receptors. For 
instance, alpha-sympathomimetic drugs induce vasoconstriction by reaction with 
adrenergic receptors located at the functional areas in vascular smooth muscle, 
but they also cause mydriasis by reaction with similar receptors in the M. di- 
lator pupillae. On the other hand cyproheptadine blocks the actions of hista­
mine and 5-hydroxytryptamine as a result of interaction with both types o f re­
ceptors.
1. D rug-receptor interaction o f a single com pound
Most drugs not only produce more than a particular pharmacological 
effect, but a particular response is produced by a chain of events.
a. Af ter injection of a drug or after swallowing a medicament, absorption into 
the bloodstream takes place, followed by distribution and elimination.
b. As a result of distribution a certain drug-concentration occurs at the level 
of the receptors.
c. Depending on the affinity towards the receptors and the concentration of the 
drug near the receptors a certain degree of receptor-occupation takes 
place.
d. Receptor-occupation may lead to the generation of a stimulus (e.g. change 
in membrane potential) depending on the intrinsic activity of the drug.
e. The stimulus in turn induces the effect. This stimulus-effect relationship 
may be very complex (thresholds and receptor reserve may be present).
Especially in the intact situation, as is the case when medicaments are given  
to patients or drugs are studied in free moving or anaesthetized animals, the 
effect is always a very complicated function of the dose administered. Fur.ther- 
more, the concentration at the level of the receptors does not remain constant in 
time (pharmacokinetics).
It is obvious that an analysis at the receptor level will be most successful 
in the simplest possible situation. These are the isolated organs, individual neu-
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rons, etc., where a particular effect, disconnected from possible other effects, 
may be studied.
In vitro it may be possible to obtain a consistent dose response relationship. 
In many cases for agonistic drugs S-shaped log dose-effect curves may be found.
2. Drug-interaction
The combination of a drug with a second drug may lead to a variety of 
interactions.
a. Antagonism: The effect of a drug may be reduced by the second drug. 
There are many causes of drug antagonism.
b. Synergism: The effect of a drug may be augmented by the second drug. 
Again there are many ways of drug interaction resulting in synergism.
In the clinicai situation many forms of drug-interaction may be encountered. 
Due to the various components in the action of a single drug and the various 
active metabolites that may be formed from the drug administered, the interac­
tion with a second drug may be very complex. Even the effect of a single drug 
may be the result of an  interaction with endogenous compounds and /o r with 
active metabolites formed in the body. Drug-interaction may be most simply be 
analyzed from a study of the change in the dose response curve produced by the 
second drug.
3. Drug-interaction at the receptor level
Also here drug-interaction may result in synergism or antagonism. If the 
second drug diminishes the response of the agonist in some way, one speaks of 
antagonism or desensitization. If the second drug augments the effect of the ago­
nist in some way, one speaks of synergism or sensitization.
Depending on the dose administered, the interaction of a given combination 
of two drugs may result in synergism at a certain dose and in antagonism at an 
other dose (also called dualistic interaction). At the level of the receptors the 
following possibilities may occur:
1. Chemical interaction (antagonism or synergism).
The interacting drug may bind to the agonistic drug there by diminishing 
the concentration of the agonist in the environment of the receptors, e.g. EDTA 
sequesters Ca++ or germanine sequesters curare.
2. Competitive interaction (antagonism, dualism or synergism).
If two or more drugs react with the same receptors, these drugs may com- 
pete with eachother for occupying receptors. Depending on the intrinsic activi- 
ty of the various drugs the interaction results in antagonism or synergism. Anta­
gonism occurs if one drug has a high and the other a low intrinsic activity. In 
case of synergism both drugs have intrinsic activity and are therefore both ago- 
nists. A drug that is inactive by itself can never produce competitive synergism.
A classical example of competitive antagonism is the combined action of 
curare and acetylcholine. The log dose-response curves shifts to the right. It must 
be realized that when atropine alone is administered to a patiënt, interaction
with endogenous acetylcholine occurs (competitive antagonism). Pilocarpine, a 
pariia] agonistic muscarinic drug, also interacts with endogenous acetylcholine 
resulting ïn synergism or antagonism depending on the level of acetylcholi­
ne present in the tissue.
5. Ailosteric interaction.
For competition it is not strictly necessary that the two drugs react with 
identical recepiors. The same phenomenon occurs in case of ailosteric interaction 
that is the two drugs react with different receptors but the two drugs either 
facilitate or impair eachother with respect to interaction with their proper re­
ceptors. In this case an inactive drug may cause a shift of the curves to the right 
(antagonism) or a shift to the left (synergism or sensitization).
4. Non-competitive interaction.
A drug may influence the response of an agonistic drug by reaction with 
other receptors and consequentlv by modifying the chain of events leading from 
receptor occupation by the agonist to the ultim ate response of the agonist. The 
non-competitive antagonist may modify the stimulus generation by the agonist in 
a positive or negative way (synergism or antagonism) or modify the relationship 
between stimulus and effect and thereby increasing or decreasing the number of 
spare receptors.
A classical example of a non-competitive antagonist is papaverine (histami- 
ne or acetylcholine as agonist). Obviously there may be a large variety of all 
kinds of non-competitive antagonists and synergists.
5. Funcfional interaction.
In fhis case two drugs react with their receptors proper leading for both 
to the generation of two different stimuli. For instance, one drug may cause an 
EPSD and the other an IPSP on the same type of neurons, so that a kind of 
antagonism occurs that is analogous to competitive interaction. A classical exam­
ple is the interaction between mecholyl and isoprenaline with respect to the to­
nus of the tracheal muscle.
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CONCLUSION
The various fornis of drug-interaction at the levcl of the receptors will be 
discussed on basis of the change in the dose-response curve they may show. The 
importance for the clinicai situation will be stvessed as far as possible.
